
BMEA Stock Forecast & Price Target
BMEA Analyst Ratings
Bulls say
Biomea Fusion Inc. is demonstrating significant progress in its clinical programs for diabetes and obesity treatments, evidenced by durable glycemic control and a favorable safety profile observed in the COVALENT-111 trial and 52-week Phase II results of icovamenib. The company has also made strides with its investigational oral GLP-1 receptor agonist, BMF-650, which has shown promising preclinical results for weight reduction and appetite suppression. Financially, Biomea reports a reduction in net loss from $32.8 million in Q3 2024 to $16.4 million in Q3 2025, alongside a more than 50% year-over-year decline in operating expenses, indicating a positive trend in financial management and operational efficiency.
Bears say
Biomea Fusion Inc. experienced a significant reduction in research and development (R&D) expenses, decreasing from $27.2 million in Q3 2024 to $14.4 million in Q3 2025, which may raise concerns about the company's commitment to advancing its clinical programs. General and administrative (G&A) expenses also declined, from $6.8 million to $4.2 million, indicating potential cost-cutting measures that could impact operational capacity. Furthermore, the adjustment in the company's price target from $16.00 to $12.00 reflects a negative reassessment of its financial outlook, suggesting growing apprehensions about its future performance and pipeline viability.
This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.
BMEA Analyst Forecast & Price Prediction
Start investing in BMEA
Order type
Buy in
Order amount
Est. shares
0 shares